Skip to content

Pulmonary Vascular Effects of Respiratory Rate & Carbon Dioxide

The Pulmonary Vascular Consequences of Divergent Strategies for Low Tidal Volume Ventilation: Hypercapnia or High Respiratory Rate?

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01927237
Enrollment
0
Registered
2013-08-22
Start date
2013-09-30
Completion date
2014-08-31
Last updated
2017-02-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Respiratory Distress Syndrome, Low Tidal Volume Ventilation

Keywords

pulmonary artery pressure, ARDS, alveolar hypoventilation, hypercapnic acidosis, permissive hypercapnia, myocardial strain

Brief summary

The purpose of this protocol is to perform serial physiological measurements and blood testing on mechanically ventilated patients comparing conditions of eucapnia and hypercapnia in the same patient. We will be testing two hypotheses: (1) while administering inspired carbon dioxide (CO2), eucapnia achieved by high respiratory rate (EHR) significantly decreases pulmonary artery pressures compared to hypercapnia with a lower respiratory rate (HLR), and (2) that EHR decreases myocardial strain compared to HLR.

Detailed description

The purpose of this protocol is to perform serial physiological measurements and blood testing on mechanically ventilated patients comparing conditions of eucapnia (maintaining alveolar ventilation to target carbon dioxide partial pressure (pCO2) 35-40 mm Hg) and hypercapnia (providing inspired CO2 to target pCO2 55-60 mm Hg) in the same patient. This prospective clinical study will enroll consenting adult patients scheduled for elective cardiac surgery and who require postoperative mechanical ventilation, pulmonary artery (Swan-Ganz) catheter monitoring, and arterial catheterization as part of routine standard care during the immediate postoperative period. The study will perform measurements using available ventilator monitors, ventilator in-line pneumotachograph and capnograph, measurements from the indwelling pulmonary artery catheter, transesophageal echocardiography, and other measurements available as part of routine care. The entire experimental protocol will be performed in one day over 2-4 hours, and the protocol will not interfere with routine postoperative care, nor prolong the need for mechanical ventilation, pulmonary artery catheterization, arterial catheterization, or intensive care unit length of stay. Ventilation with low tidal volumes has been shown definitively to improve mortality from acute respiratory distress syndrome (ARDS)1 and may provide benefit even in patients without ARDS.2 During low tidal volume ventilation, practice varies on whether to allow some degree of alveolar hypoventilation with incidental hypercapnic acidosis (termed permissive hypercapnia),3 or to increase respiratory rate to maintain alveolar ventilation and target eucapnia, often requiring respiratory rates \> 30/min.4 The physiological consequences of these divergent strategies remain to be fully elucidated. We propose the following study to distinguish the effects of a eucapnic high respiratory rate (EHR) strategy from a hypercapnic low respiratory rate (HLR) strategy on pulmonary hemodynamics during low tidal volume ventilation. Specific Aim: To test the hypothesis that, while administering inspired CO2, eucapnia achieved by high respiratory rate (EHR) significantly decreases pulmonary artery pressures compared to hypercapnia with a lower respiratory rate (HLR). Specific Aim: To test the hypothesis that EHR decreases myocardial strain compared to HLR.

Interventions

OTHERHLR
OTHEREHR

Sponsors

Beth Israel Deaconess Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

* Age ≥ 18 years old. * Able to consent pre-operatively prior to scheduled cardiac surgery. * Intubation on mechanical ventilation post-operatively. * Presence of a pulmonary artery catheter and/or central venous catheter as part of usual care post-operatively. * Presence of a radial, brachial, or femoral arterial catheter as part of usual care post-operatively.

Exclusion criteria

* Significant intra-operative or immediate post-operative complications, such as uncontrolled bleeding or persistent hemodynamic instability. * Intra-cardiac or intrapulmonary shunt. * Persistent post-operative moderate or severe hypoxemia, defined as PaO2/FiO2 \< 200 mmHg. * Moderate or severe lung disease, including moderate or severe chronic obstructive pulmonary disease (COPD) or asthma. * Recently treated for bleeding varices, stricture, or hematemesis, esophageal trauma, recent esophageal surgery, or other contraindication to transesophageal echocardiography. * Severe coagulopathy (platelet count \< 10,000 or international normalized ratio \[INR\] \> 4). * History of lung, heart, or liver transplant. * Elevated intracranial pressure or conditions where hypercapnia-induced elevations in intracranial pressure should be avoided, including: * Intracranial hemorrhage * Cerebral contusion * Cerebral edema * Mass effect (midline shift on head CT) * Flat EEG for \> 2 hours * Evidence of active air leak from the lung, such as broncho-pleural fistula or ongoing air leak from an existing chest tube. * Treating physician refusal. * Inability to obtain informed consent directly from the subject prior to surgery.

Design outcomes

Primary

MeasureTime frameDescription
mean pulmonary artery pressure (mPAP)4 hoursPulmonary artery pressure will be measured directly by transducing the pulmonary artery catheter, and will include systolic (PASP) and diastolic (PADP) Ppa. The mean pulmonary artery pressure (mPAP) will be calculated according to the formula: mPAP = 1/3 PASP + 2/3 PADP

Secondary

MeasureTime frameDescription
Right ventricular systolic function4 hoursRight ventricular systolic function will be assessed using strain echocardiography or peak tricuspid annular systolic velocity.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026